📊 Income Statement ▲
Revenue by Product
VAZALORE 81 mg DoseVAZALOREVAZALORE 325 mg Dose
Revenue by Geography
Revenue, Gross Profit, Operating and Net Income
RevenueGross ProfitOperating IncomeNet Income
Margin (%)
Gross MarginOperating MarginNet Income Margin
Operating Expenses
Research And Development ExpensesSelling And Marketing ExpensesGeneral And Administrative Expenses
EBITDA
EBITDA
EPS
EPSEPS Diluted
Revenue Variation (%)
Revenue Variation
Income Variation (%)
Gross Profit VariationOperating Income VariationNet Income Variation
Revenue YoY Variation (%)
Revenue YoY Variation
Income YoY Variation (%)
Gross Profit YoY VariationOperating Income YoY VariationNet Income YoY Variation
Price-to-Earning Ratio
P/E Ratio
Income Breakdown
Operating IncomeTotal Other Income Expenses NetNet Income
Per Share Metrics
Revenue Per ShareNet Income Per ShareOperating Cash Flow Per Share
Expense Ratios
Research And Ddevelopement To RevenueStock Based Compensation To Revenue
💰 Cash Flow Statement ▲
Operating Cash Flow
Free Cash Flow
Cash At End Of Period
Cash Flow to Debt Ratio
Net Cash Provided By Operating ActivitiesNet Cash Used Provided By Financing Activities
🏦 Balance Sheet ▼
📈 Key Metrics ▼